BlossomHill Therapeutics, Inc. (BLSM) — IPO Dossier

A clinical-stage oncology company with two candidates in the clinic, a going-concern paragraph and a reverse split effected three days before terms, marketing 7,812,500 shares at $15.00-$17.00.